Robbins Farley’s AstraZeneca AZN Stock Holding History

Robbins Farley’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.96M	Buy	25,137 +184	+0.7%	+$35.5K	2.19%	19
2025 Q4	$4.59M	Sell	24,953 -2,122	-8%	-$372K	2.08%	22
2025 Q3	$4.15M	Buy	27,075 +13,791	+104%	+$2.09M	1.73%	29
2025 Q2	$1.86M	Buy	+13,284	New	+$1.86M	0.86%	45
2023 Q4	–	Sell	-200	Closed	-$27.1K	–	178
2023 Q3	$27.1K	Hold	200	–	–	0.02%	95
2023 Q2	$28.6K	Hold	200	–	–	0.02%	85
2023 Q1	$27.8K	Hold	200	–	–	0.02%	89
2022 Q4	$27.1K	Hold	200	–	–	0.02%	84
2022 Q3	$22K	Hold	200	–	–	0.02%	78
2022 Q2	$26K	Buy	+200	New	+$26.2K	0.03%	58
2022 Q1	–	Sell	-200	Closed	-$23K	–	132
2021 Q4	$23K	Hold	200	–	–	0.02%	69
2021 Q3	$24K	Hold	200	–	–	0.02%	77
2021 Q2	$24K	Hold	200	–	–	0.03%	47
2021 Q1	$22K	Buy	+200	New	+$20.1K	0.02%	78

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Robbins Farley's AZN Position: Q1 2026 in Review

Robbins Farley increased its AstraZeneca (AZN) stake by 0.74% in Q1 2026, buying an estimated $35.5K and bringing the position to 25,137 shares worth $4.96M. The position accounts for 2.19% of the portfolio, ranked #19.

Robbins Farley first reported a position in AZN in Q1 2021 and has held it in 14 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Robbins Farley held 25,137 shares of AstraZeneca worth $4.96M as of Q1 2026.
Robbins Farley bought 184 AstraZeneca shares in Q1 2026, an estimated $35.5K.
AstraZeneca made up 2.19% of Robbins Farley's portfolio in Q1 2026, its #19 holding.
Robbins Farley first reported a position in AstraZeneca in Q1 2021 and has held it in 14 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Robbins Farley's 13F filing for Q1 2026, filed 17 Apr 2026.